<DOC>
	<DOCNO>NCT02209363</DOCNO>
	<brief_summary>Cognitive dysfunction ( impaired memory , thinking , etc ) frequently occur Parkinson 's disease ( PD ) , often progress dementia , profoundly affect quality life . Obstructive sleep apnea ( OSA ) common disorder general population treatable positive airway pressure ( PAP ) therapy . It known impair cognitive function , whether treatment improves cognitive function less clear . When already affect degenerative process like PD , brain might vulnerable effect OSA , responsive OSA treatment . To date , OSA recognize significant factor PD . In preliminary work PD patient , investigator find association OSA poor cognition , cognitive improvement PAP therapy . The investigator wish rigorously evaluate effect OSA treatment cognitive function PD randomize control trial . The investigator primary objective ass , PD patient OSA cognitive deficit , effect OSA treatment global cognitive function . The investigator also assess non-motor symptom PD , quality life , specific domain neurocognitive function . PD patient recruit McGill Movement Disorders Clinic Quebec Parkinson Network Centres . Participants need evidence cognitive deficit presence OSA screen diagnostic polysomnography ( sleep study ) . Ninety subject randomly assign PAP nasal dilator strip . Detailed neuropsychological testing measurement ( include quality life ) do baseline , 3 month 6 month . At end study period , subject polysomnography respective treatment ass efficacy respect OSA treatment . This study may demonstrate non-pharmacologic intervention potential mark beneficial impact cognitive function quality life significant proportion PD patient .</brief_summary>
	<brief_title>Cognition Obstructive Sleep Apnea Parkinson 's Disease , Effect Positive Airway Pressure Therapy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Idiopathic Parkinson 's disease per UK Parkinson 's Disease Society Brain Bank criterion Evidence cognitive dysfunction ( clinical impression mild cognitive impairment MOCA &lt; 27 ) Presence OSA ( apneahypopnea index AHI â‰¥ 15/h ) screen diagnostic polysomnography ( PSG ) Stable regimen antiPD medication 1 month prior trial Adequate knowledge English French completion study assessment . Oxygen saturation &lt; 75 % &gt; 10 % diagnostic polysomnography lead active PAP treatment Other major neurological disorder Unstable cardiac disease , uncontrolled hypertension , diabetes Active cancer disorder expect survival &lt; 6 month Active treatment OSA ( prior diagnosis OSA constitute exclusion criterion patient currently treat OSA ) Significant vision hearing impairment could affect performance neurocognitive assessment task . Latex allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>OSA</keyword>
	<keyword>CPAP</keyword>
	<keyword>cognition</keyword>
</DOC>